Affiliation:
1. Hillside College of Pharmacy & Research Centre.
Abstract
An oral modied release dosage forms have always been more effective therapeutic alternative to conventional dosage forms. The present
invention is directed to a modied release pharmaceutical composition of indomethacin by using hydrophilic release retardant polymers like
HPMC K15M, Na CMC alone or in combination. Matrix embedded prolong release tablet formulations of Indomethacin were prepared by wet
granulation technique and evaluated for tablet properties such as the thickness, hardness, friability, weight variation, drug content, drug release
kinetics and in vitro release studies. The inuence of drug polymer ratio on drug release was studied by dissolution test. The FTIR studies showed
no interactions among drug and polymers. The tablets formulation (F7 and F8) containing combined polymers of HPMC K15M and Na CMC
resulted in slower drug release rate form the matrix. So, it can be concluded that Indomethacin prolong release tablets using HPMC K15M and Na
CMC as the retardant has successfully extended the release of indomethacin from its formulations. The mixing of two cellulose polymers, ionic and
non-ionic, for the formulation of hydrophilic matrices, resulted in a valuable decrease in drug release rate. All the formulations showed KorsmeyerPeppa’s model as a best t.
Reference22 articles.
1. Hucker Hb, Zacchei A G, Cox S Y, Brodie D A And Cantwell N H R: Studies on the absorption, distribution and excretion of indomethacin in various species. The Journal of Pharmacology and Experimental Therapeutics 1966; 153(2):237-249
2. Helleberg L: Clinical pharmacokinetics of indomethacin. Clinical Pharmacokinetics 1981;6(4):245-58
3. Kuang C. and Yeh Ph.D: Pharmacokinetic overview of indomethacin and sustained-release indomethacin. The American Journal of Medicine 1985; 79(4):3-12
4. Dempski RE, Mehta GN and Saboe JC: Sustained release indomethacin. US patent US4173626A 1978
5. Mehta AM: Controlled release indomethacin. WO1988003796A1 1987